Summary
PREDICT1 is a prospective observational study conducted in Japan investigating proteomic biomarkers in pre-treatment blood serum that may predict clinical benefit from carboplatin-pemetrexed chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer. Using mass spectrometry-based proteomics, the researchers developed a classifier to identify optimal treatment candidates, contributing to precision oncology approaches in a population lacking actionable molecular alterations. The study addresses a significant clinical gap in treatment selection for this chemotherapy regimen.
UK applicability
The proteomic biomarker findings could support precision medicine approaches in UK oncology services, though validation in UK or European populations would strengthen clinical applicability. Implementation would require integration with existing NHS pathways for advanced lung cancer diagnosis and treatment planning.
Key measures
Blood serum proteomic profiles; treatment response stratification; classifier performance for predicting clinical benefit from CbP chemotherapy
Outcomes reported
The study identified blood serum proteomic biomarkers associated with clinical benefit from carboplatin-pemetrexed chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer. Researchers developed a classifier to stratify patients by treatment response based on pre-treatment blood samples analysed using mass spectrometry-based proteomics.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.